These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20864811)

  • 1. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.
    Li X; Lu Y; Pan T; Fan Z
    Autophagy; 2010 Nov; 6(8):1066-77. PubMed ID: 20864811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.
    Li X; Fan Z
    Cancer Res; 2010 Jul; 70(14):5942-52. PubMed ID: 20634405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
    Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
    Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
    Bianco R; Garofalo S; Rosa R; Damiano V; Gelardi T; Daniele G; Marciano R; Ciardiello F; Tortora G
    Br J Cancer; 2008 Mar; 98(5):923-30. PubMed ID: 18319715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
    Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
    Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
    Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
    PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
    Li X; Lu Y; Liang K; Pan T; Mendelsohn J; Fan Z
    Mol Cancer Ther; 2008 May; 7(5):1207-17. PubMed ID: 18483308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.
    Lu Y; Li X; Lu H; Fan Z
    PLoS One; 2010 Dec; 5(12):e15823. PubMed ID: 21209911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.
    Chen W; Hu QD; Xia XF; Liang C; Liu H; Zhang Q; Ma T; Liang F; Liang TB
    Cancer Biol Ther; 2014 Aug; 15(8):992-9. PubMed ID: 24800850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
    Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
    Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.